In a move poised to redefine the synthetic biology supply chain, Integrated DNA Technologies (IDT) and next-gen DNA manufacturing company Elegen have announced a strategic partnership aimed at transforming how scientists access long, high-complexity genes.

The early access program, launching today, grants IDT customers a new synthetic biology capability: Elegen’s ENFINIA™ Plasmid DNA service. The service enables rapid delivery of clonal genes ranging from 5 kb to 15 kb—NGS-verified and shipped from Elegen’s U.S.-based facility within 10 business days. That’s a speed and scale rarely seen in long DNA synthesis, a space often plagued by lengthy timelines and steep costs.

“This collaboration allows Elegen to expand access to our ENFINIA™ Plasmid DNA and equip researchers rapid access to longer and more complex DNA sequences—capabilities that have historically been limited in the market,” said Matthew Hill, PhD, founder and CEO of Elegen. “We believe this partnership will accelerate research and development across the industry, driving innovation and breakthroughs in the life sciences.”

A Stronger Synthetic Biology Portfolio

For IDT, the partnership enhances an already deep synthetic biology portfolio. In addition to gene and gene fragment offerings, the company supports a variety of plate formats, high-throughput workflows, and custom solutions tailored by a dedicated team of synthetic biology experts.

“IDT has continued to bolster its synthetic biology offerings and capabilities with new products and enhancements, as well as a U.S. facility expansion, to boost our throughput and efficiency over the last 12 months,” said Sandy Ottensmann, VP/General Manager, Gene Writing & Editing Business Unit at IDT. “Our partnership with Elegen allows us to offer customers competitively priced long and complex DNA that they can pair with IDT’s extensive portfolio of custom synthetic biology solutions.”

The integration of Elegen’s technology gives IDT the ability to address growing demand for longer, high-fidelity DNA, opening new opportunities for advanced research in areas such as cell and gene therapy, metabolic engineering, and synthetic genomes.

Driving Industry Innovation

As biotech research continues to demand more complex genetic constructs, speed and accuracy are paramount. Traditional gene synthesis methods struggle to deliver long and intricate DNA sequences in a timely and cost-effective manner. The IDT–Elegen partnership directly tackles these pain points, providing scientists with tools to move faster from concept to experiment.

For both companies, it’s a signal that the synthetic biology race is accelerating—and they're building the track.